ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY

Clinical trials for ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY explained in plain language.

Never miss a new study

Get alerted when new ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY trials appear

Sign up with your email to follow new studies for ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug trial targets rare, debilitating nerve disorder

Disease control Not yet recruiting

This study is testing whether a drug called zanubrutinib can improve nerve function in people with a rare immune disorder called anti-MAG neuropathy. About 50 adults with confirmed diagnosis and measurable nerve disability will take the drug for 12 months to see if their neurolog…

Matched conditions: ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY

Phase: PHASE2 • Sponsor: Azienda Ospedaliera di Padova • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY

Get alerted when new ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY trials appear

New drug trial targets rare, debilitating nerve disorder